Business Update Neutral

2026-08-11 16:21

- Investors' Meet Schedule - Meeting Date: 14-Aug-26 - Event: Emkay - Confluence 2026 - Type of Meeting: Group and one on one

Business Update Positive

2026-08-11 14:52

- Torrent Pharmaceuticals received an Environmental, Social, and Governance (ESG) Rating of 70 from NSE Sustainability Ratings and Analytics Limited, a SEBI registered ESG Rating Provider.

Governance Neutral

2026-08-05 17:46

- Torrent Pharmaceuticals Limited announced a Postal Ballot for the appointment of Ms. Shanti Ekambaram as an Independent Director for a term of 3 years. - The e-voting period is from August 08, 2026 (9:00 AM IST) to September 06, 2026 (5:00 PM IST). - Results will be announced on or before September 08, 2026.

Business Update Neutral

2026-08-04 12:27

- Transcript of the conference call with analysts/investors on financial results for the quarter ended June 30, 2026, has been placed on the company's website.

Governance Neutral

2026-08-01 21:28

- Intimation regarding the cessation of an Independent Director. - Ameera Shah (DIN: 00208095) ceased to be an Independent Director of Torrent Pharmaceuticals Limited on August 01, 2026. - The cessation is due to the completion of her term.

Business Update Neutral

2026-07-30 19:37

- Audio recording of the conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026, has been made available. - The recording is accessible on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording30062026.mp3.

Governance Neutral

2026-07-30 17:04

- Torrent Pharmaceuticals Limited informed that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni ceased to be Senior Management Personnel (SMPs). - This change is effective from July 30, 2026, due to a change in reporting structure.

Financials Negative

2026-07-30 16:53

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹4,921Cr vs ₹3,178Cr (▲55% YoY) - EBITDA ₹1,664Cr vs ₹1,032Cr (▲61% YoY) - PAT ₹566Cr vs ₹548Cr (▲3% YoY) - EBITDA Margin 33.8% vs 32.5% (▲130bps)

Financials Positive

2026-07-30 16:51

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹4,921Cr vs ₹3,178Cr (▲55% YoY) - Op. EBITDA ₹1,664Cr vs ₹1,032Cr (▲61% YoY) - PAT ₹566Cr vs ₹548Cr (▲3% YoY) - Op. EBITDA Margin 33.8% vs 32.5% (▲130bps)

Governance Positive

2026-07-28 09:38

- Board approved the appointment of Shanti Ekambaram as an Additional Independent Director for a 3-year term, effective July 30, 2026, subject to shareholder approval. She brings 39 years of financial services experience from Kotak Mahindra Bank.

Business Update Positive

2026-07-27 19:08

- Torrent Pharma received final listing and trading approval for 4,19,22,416 equity shares. - These shares were issued as part of the amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. - Listing and trading on NSE and BSE will commence from July 28, 2026.

Ownership Positive

2026-07-20 12:46

- Torrent Pharma allotted 4,19,22,416 fully paid-up equity shares on July 20, 2026, to eligible shareholders of J. B. Chemicals & Pharmaceuticals Ltd. - This is pursuant to the scheme of amalgamation, with a record date of July 17, 2026. - The company's issued equity share capital increased from ₹1,69.22 Cr (33.84 Cr shares) to ₹1,90.18 Cr (38.03 Cr shares).

Business Update Neutral

2026-07-17 22:42

- Torrent Pharmaceuticals Limited announced the voluntary dissolution of its wholly-owned subsidiary, Curatio Inc., Philippines, effective July 10, 2026. - The dissolved subsidiary had Nil turnover and a net worth of Rs 1.3 Crores (0.02% of the listed entity's net worth) for FY 2025-26.

Business Update Neutral

2026-07-17 22:41

- Torrent Pharmaceuticals Limited announced that Crisil ESG Ratings & Analytics Limited has assigned the rating of ‘Crisil ESG 66' and the Core ESG rating of 'Crisil Core ESG 74' on July 17, 2026.

Business Update Neutral

2026-07-17 19:08

- Concall Schedule - Concall Date: 30th July, 2026 - Concall Time: 05:30 P.M.

Business Update Negative

2026-07-09 17:36

- Torrent Pharmaceuticals initiated a voluntary recall of select batches of Semalix injection disposable pens (2mg & 4mg). - This precautionary measure follows a technical evaluation by the manufacturer, Dr. Reddy's Laboratories Ltd. - The company confirmed no risk to patients currently on treatment and other Semaglutide products are unaffected.

Business Update Positive

2026-07-08 10:23

- The Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited became effective on 8th July, 2026, following NCLT approval. - J.B. Chemicals is now amalgamated into Torrent Pharma and dissolved. - The capital clause of Torrent Pharma's Memorandum of Association has been amended, reflecting a total capital of ₹2,55,30,00,000.

Business Update Positive

2026-07-08 10:21

- The Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited became effective on July 8, 2026. - J.B. Chemicals is now amalgamated into Torrent Pharma and dissolved. - Torrent Pharma's capital clause was amended to ₹2,55,30,00,000.

Routine Neutral

2026-07-07 20:01

New Filing detected. See link for details.

Business Update Positive

2026-07-07 18:07

- NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited via an Order dated 6th July 2026. - The company received the certified true copy of the Order on 7th July 2026.

Business Update Positive

2026-07-06 18:48

- NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited on July 6, 2026. - The scheme will become effective upon filing the certified copy of the Order with the Registrar of Companies.

Routine Neutral

2026-06-26 10:05

- The trading window for Designated Persons will be closed from July 1, 2026. - It will reopen 48 hours after the submission of financial results for the quarter ended June 30, 2026.

Governance Positive

2026-06-23 17:30

- Torrent Pharma's 53rd AGM results (June 23, 2026) declared. - All resolutions passed, including FY26 financial statements adoption and dividends (₹29 interim, ₹9 final). - Re-appointment of Director Samir Mehta and approval for equity/convertible bond issuance also passed.

Governance Positive

2026-06-23 17:15

- The 53rd AGM approved Standalone and Consolidated Financial Statements for the year ended March 31, 2026. - Confirmed payment of interim dividend of ₹29.00 and declared a final dividend of ₹9.00 per equity share for FY26. - Approved the re-appointment of Director Samir Mehta and the issuance of Equity Shares/Convertible Bonds/Debentures.

Governance Neutral

2026-06-03 18:55

- Torrent Pharmaceuticals announced its 53rd Annual General Meeting (AGM) will be held on June 23, 2026, at 9:30 A.M. (IST) via Video Conference. - The company has provided a weblink for shareholders to access the Notice of the AGM and Integrated Annual Report for FY 2025-26.

Business Update Negative

2026-06-01 19:47

CRITICAL RED FLAG DETECTED

- Torrent Pharmaceuticals filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - It includes Grant Thornton Bharat LLP's assurance report. - The company reported regulatory fines/penalties exceeding ₹49 Cr for FY 2025-26, primarily for alleged drug overcharging and ITC/refund issues.

Business Update Neutral

2026-05-30 10:49

Torrent Pharmaceuticals Limited announced the schedule for its upcoming investor meetings. Company representatives will participate in the BoFA 2026 India Conference on June 3, 2026, and Citi's 2026 India Conference on June 4, 2026. Both events will be held in Mumbai and will include group and one-on-one meetings.

Business Update Neutral

2026-05-27 17:26

Torrent Pharmaceuticals Limited has informed the exchanges that the transcript of its conference call with analysts and investors on the audited financial results for the quarter and year ended 31st March, 2026, has been placed on the company's website.

Business Update Neutral

2026-05-22 20:02

Torrent Pharmaceuticals Limited announced the availability of the audio recording of its conference call with analysts/investors on the audited financial results for the quarter and year ended March 31, 2026. The recording has been placed on the company's website.

Financials Positive

2026-05-22 17:08

Torrent Pharmaceuticals Limited has fixed Friday, May 29, 2026, as the Record Date for determining shareholders eligible for the final dividend for the year 2025-26, if declared.

Financials Positive

2026-05-22 16:57

Torrent Pharmaceuticals reported standalone Q4 FY26 Total Revenue from Operations of ₹2,735 Cr vs ₹2,433 Cr (▲12.41% YoY), EBITDA of ₹956 Cr vs ₹844 Cr (▲13.27% YoY), and PAT of ₹467 Cr vs ₹474 Cr (▼1.48% YoY). EBITDA Margin was 34.95% vs 34.69% (▲26 bps). The Board recommended a final dividend of ₹9/- (180%) per equity share and proposed an enabling approval for Qualified Institutional Placement (QIP) of up to ₹5,000 crores.

Financials Positive

2026-05-22 16:54

Torrent Pharmaceuticals reported Consolidated Revenue of ₹4,197Cr vs ₹2,959Cr (▲41.84% YoY), EBITDA of ₹1,290Cr vs ₹940Cr (▲37.23% YoY), and PAT of ₹364Cr vs ₹498Cr (▼26.91% YoY). EBITDA Margin was 30.74% vs 31.77% (▼103bps). The decline in PAT and margin contraction is primarily due to exceptional items and increased finance costs associated with the acquisition of JB Pharma. The Board recommended a final dividend of ₹9/- per equity share and approved seeking enabling approval for a Qualified Institutional Placement (QIP) of up to ₹5,000 crores.

Financials Positive

2026-05-22 16:52

Standalone Revenue ₹2,793Cr vs ₹2,448Cr (▲14.09% YoY), EBITDA ₹1,003Cr vs ₹868Cr (▲15.55% YoY), PAT ₹467Cr vs ₹474Cr (▼1.48% YoY). EBITDA Margin 35.98% vs 35.46% (▲52bps).

Routine Neutral

2026-05-22 16:51

New Filing detected. See link for details.

Business Update Neutral

2026-05-16 18:35

Torrent Pharmaceuticals Limited announced the rescheduling of its post quarterly financial result conference call with investors/analysts. The call, originally scheduled for 06:30 P.M. on May 22, 2026, to discuss the financial performance for the quarter and year ended March 31, 2026, has been moved to 05:30 P.M. on the same day. The dial-in details remain unchanged.

Routine Neutral

2026-05-12 16:45

New Filing detected. See link for details.

Business Update Neutral

2026-05-12 15:06

Torrent Pharmaceuticals Limited has scheduled a teleconference with investors and analysts on 22nd May, 2026, at 06:30 P.M. to discuss the financial performance of the company for the quarter and year ended 31st March, 2026. The filing includes universal and international dial-in information along with a Diamond Pass Registration link for participants.

Governance Positive

2026-04-28 22:58

Torrent Pharmaceuticals Limited announced that its Equity Shareholders, at an NCLT convened meeting on April 28, 2026, approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The resolution was passed by the requisite majority, with approximately 99.33% of shareholders (by number) voting in favour during remote e-voting and 100% during e-voting at the meeting.

Governance Positive

2026-04-28 22:38

Torrent Pharmaceuticals Limited announced that its Equity Shareholders, at an NCLT-convened meeting held on April 28, 2026, approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited by requisite majority.

Governance Positive

2026-04-28 21:07

Torrent Pharmaceuticals Limited announced that the NCLT convened meeting of its Equity Shareholders was held on April 28, 2026. During the meeting, the proposed Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited (JB Pharma) with Torrent Pharmaceuticals Limited was duly approved by the Equity Shareholders with the requisite majority.

Routine Neutral

2026-04-10 19:08

New Filing detected. See link for details.

Business Update Neutral

2026-03-30 20:09

Torrent Pharmaceuticals Limited sold 50,000 equity shares of UNM Foundation (an associate Section 8 company with no turnover) for ₹5,00,000 to its Holding Company, Torrent Investments Limited, on March 30, 2026. This was a related party transaction.

Routine Neutral

2026-03-28 12:26

Torrent Pharmaceuticals Limited announced the closure of its trading window for designated persons from April 1, 2026. It will reopen 48 hours after the submission of the Audited Financial Results for the Financial Year ended March 31, 2026.

Business Update Neutral

2026-03-28 10:44

Torrent Pharmaceuticals will hold a shareholder meeting on April 28, 2026, via Video Conferencing, to approve the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. This meeting is pursuant to an order from the National Company Law Tribunal.

Routine Neutral

2026-03-27 20:27

New Filing detected. See link for details.

Business Update Neutral

2026-03-25 20:07

Torrent Pharmaceuticals informed about a Corrigendum Order issued by the NCLT on March 24, 2026, related to the proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The order, which pertains to a Scheme of Amalgamation, was uploaded on the NCLT website on March 25, 2026.

Business Update Positive

2026-03-24 19:10

Torrent Pharmaceuticals Limited announced that the NCLT Ahmedabad Bench has uploaded the Order on 23rd March, 2026, regarding the first motion application for its proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited.

Business Update Positive

2026-03-21 14:01

Torrent Pharma launched oral and injectable formulations of Semaglutide (brands Sembolic and Semalix) in India, becoming the first Indian company to offer generic oral Semaglutide at Rs. 3,999 per month. This expands its presence in the type-2 diabetes and obesity market, aiming to provide affordable treatment options.

Business Update Neutral

2026-02-25 19:28

Torrent Pharma announced a schedule of investor meetings with institutional investors in Singapore (March 2-4), Hongkong (March 5-6), and London (March 9-12) in March 2026, as per SEBI Regulation 30.

Business Update Neutral

2026-02-20 18:47

Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and nine months ended 31st December, 2025, has been placed on the Company's website.

Business Update Neutral

2026-02-13 19:46

Torrent Pharmaceuticals announced that the audio recording of the conference call with analysts/investors on financial results for the quarter and nine months ended 31st December, 2025, has been placed on its website.

Financials Positive

2026-02-13 17:12

Board approved Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025. An interim dividend of ₹29/- (580%) per equity share was declared, payable around March 6, 2026.

Financials Positive

2026-02-13 17:07

Standalone Revenue ₹2,591Cr vs ₹2,380Cr (▲9% YoY), EBITDA ₹992Cr vs ₹890Cr (▲11.5% YoY), PAT ₹577Cr vs ₹485Cr (▲19% YoY). EBITDA Margin 38.29% vs 37.39% (▲90bps). The board also declared an interim dividend of ₹29 per equity share.

Financials Positive

2026-02-13 17:03

Consolidated Revenue ₹3,303Cr for Q3 FY26 vs ₹2,809Cr for Q3 FY25 (▲18% YoY).

Financials Positive

2026-02-13 17:02

The Board approved audited standalone and unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. An interim dividend of ₹29/- (580%) per equity share was recommended, expected to be paid around March 6, 2026.

Financials Positive

2026-02-13 17:02

The Board approved Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025. An interim dividend of ₹29/- (580%) per equity share was declared, payable around March 6, 2026.

Financials Positive

2026-02-13 16:54

The Board approved unaudited consolidated financial results for the quarter ended December 31, 2025, and declared an interim dividend of ₹29/- (580%) per equity share of ₹5/- fully paid up, payable around March 6, 2026. Detailed financial figures were not provided in this filing.

Business Update Positive

2026-02-11 21:42

Torrent Pharma announced its schedule for investor meetings in Mumbai. The company will participate in institutional investor meetings from Feb 16-19, 2026, the Kotak - Chasing Growth 2026 Investor Conference on Feb 23, 2026, and the IIFL - Enterprising India Investor Conference on Feb 24, 2026.

Routine Neutral

2026-02-03 22:04

New Filing detected. See link for details.

Financials Positive

2026-02-03 18:53

Torrent Pharmaceuticals has fixed Thursday, February 19, 2026, as the Record Date for determining shareholders eligible for an Interim Dividend, if declared by the Board on February 13, 2026.

TORNTPHARM

Torrent Pharmaceuticals Limited

Price Chart

Filing History

Unlock Full History